Page 125 - Read Online
P. 125

García Botero et al. Plast Aesthet Res 2018;5:15  I  http://dx.doi.org/10.20517/2347-9264.2018.09                                Page 7 of 8

               two applications per patient. The incidence of effective granulation ≥ 75% of the ulcer size was observed in
                                                             [9]
               76.5% of the patients at 5 weeks of treatment initiation . Also, we found a report case of seven patients with
               chronic venous ulcers treated with cultured keratinocytes which were transplanted in a fibrin matrix. Results
               showed complete ulcer healing in four of seven ulcers treated, with a mean healing time of 14.5 weeks .
                                                                                                        [15]
               However, it was not possible to conclude that completed ulcer healing was a consequence of the presence
               of fibrin matrix or cultured keratinocytes. The authors suggest, based on in vitro and in vivo studies, that
               the fibrin residue in cultured keratinocytes may inhibit complete wound healing after the transplantation.
               Therefore, the use of low density fibrin, instead of high density, to enhance grafting, keratinocytes survival
               and epithelialization was recommended.


               Study limitations
               The major limitation of the present study is the few studies available evaluating the management of venous
               ulcer with fibrin matrix and with or without growth factors. Most studies evaluated ulcers from different
               etiologies and ulcer management was done with a combination of fibrin matrix with different products
               or non-fibrin matrices. Therefore, it was not possible to perform a meaningful analysis of this type of
               intervention.


               Conclusions
               This review has not identified conclusive evidence for the use of fibrin matrices with or without growth
               factors in patients with venous leg ulcers. We found only a few studies that evaluated the results of this
               intervention.



               DECLARATIONS
               Authors’ contributions
               Study conception and design, critical revision: García Botero A
               Acquisition of data, critical revision: Cantini Ardila JE
               Analysis and Interpretation of data, critical revision: Devoz Borja LD
               Drafting of manuscript, critical revision: Gómez-Ortega V


               Data source and availability
               Article searches were performed in MEDLINE, EMBASE, COCHRANE, LILACS and ongoing clinical trials
               at ClinicalTrial.gov.


               Financial support and sponsorship
               None.


               Conflicts of interest
               There are no conflicts of interest.

               Patient consent
               Not applicable.

               Ethics approval
               Not applicable.


               Copyright
               © The Author(s) 2018.
   120   121   122   123   124   125   126   127   128   129   130